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Abstract
Although critically ill patients represent a vulnerable group of individuals, guidelines in research ethics assert that
ethically acceptable research may proceed with such vulnerable subjects if additional safeguards are in place to
minimize the risk of harm and exploitation. Such safeguards include the proper obtainment of informed consent
that avoids the presence of the therapeutic misconception and the assessment of decisional capacity in critically ill
patients recruited for research. Also discussed in this review are additional safeguards for such vulnerable subjects,
as well as the issues involved with proxy consent. Heightened awareness to principles of ethics and provision of
additional safeguards to enhance protections of vulnerable subjects would help to maintain the public trust in the
research endeavor.
Introduction
Critical care research presents special ethical challenges
largely due to the potential for exploitation stemming
from the vulnerability of the critically ill patients who
are solicited for enrollment. Vulnerability refers to the
inability to protect oneself and can be due to intrinsic
(e.g., deficits in decision-making capacity) and situa-
tional factors that threaten voluntary choice (e.g., coer-
cive settings or undue inducements) [1,2]. The presence
of vulnerability makes the achievement of a valid,
informed consent problematic. Nonetheless, consensus
statements on research ethics assert that ethically accep-
table research may proceed with such vulnerable sub-
jects if additional safeguards are in place to minimize
the risk of harm and exploitation [2-5].
However, research involving critically ill patients
remains problematic due to the lack of guidance on
how to protect vulnerable subjects adequately [1,6]. For
example, the U.S. Common Rule’s general provisions
merely direct Institutional Review Boards (IRBs) to
include “additional safeguards...to protect the rights and
welfare” of “mentally disabled persons” [7]. Similar lack
of guidance as well as ambiguity has been raised with
the European Union Directive [8,9]. In the absence of
the specification of at least the essential safeguards, the
protection of vulnerable subjects relies too heavily on
the views of diverse IRBs, leading to insufficient protec-
tion of vulnerable subjects [10]. For example, in its
investigation of critical care trials, the Office for Human
Research Protections (OHRP) found that most IRBs
failed to require additional safeguards beyond that of
requiring proxy consent [11]. In a cross-sectional survey
of IRBs in U.S. institutions, investigators showed that
IRBs rarely or never required procedures to determine
capacity and also varied in their use of other safeguards,
such as independent monitors, research proxies, and
advance research directives [10].
This article is designed to review a) the issues involved
with the decision-making capacity of critically ill
patients, b) the methods of capacity assessment, and c)
the potential concerns regarding proxy consent. A fra-
mework is also presented to outline specific core safe-
guards linked to risk levels that will minimize the
possibility of exploitation of critically ill patients who
are asked to enroll in clinical trials.
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provided the original work is properly cited.Informed consent and the capacity to consent
Informed consent provides research subjects a mechan-
ism to protect themselves. Such a protection mechanism
is necessary, because unlike in the clinical setting in
w h i c ht h ei n t e r e s t so fp a t i e n t sa n dd o c t o r sc o n v e r g e ,
researchers’ interests in obtaining valid scientific data
can conflict with their obligation to protect the rights
and welfare of the research participants.
Critical care investigators face a difficult task of recruit-
ing research subjects who may have diminished capacity
to understand information, appreciate the situation they
are in, and to make complex decisions. Indeed, studies
have shown that patients with acute illnesses may have
limitations in their decision-making capabilities due to a
number of factors, including the presence of delirium,
their underlying illness, or the use of sedatives and analge-
sics [11-16]. The presence of these factors does not neces-
sarily translate into incapacity to provide a valid informed
consent to research. Indeed, two types of errors can occur
in the setting of obtaining informed consent from critically
ill patients. One, surrogate consent is obtained for patients
who are capable of providing consent, thus depriving such
patients their autonomy rights to choose for themselves.
The opposite error occurs when investigators obtain
informed consent from patients who lack decisional capa-
city, thus making them vulnerable to exploitation. Several
studies have documented that many enrolled subjects have
limited understanding of the research to which they pro-
vided consent [17-20].
Another issue with the proper obtainment of informed
consent involves the ability of research participants to
distinguish between research and clinical care [21].
“Therapeutic misconception” (TM) is used to describe
this phenomenon, a term first reported by Appelbaum
and colleagues in 1982 during interviews with patients
with psychiatric disorders who participated in clinical
trials [22]. Indeed, several empirical studies have shown
that individuals participating in clinical research miscon-
strue a therapeutic intention to the research procedures
in a study [23-26].
Investigators have identified two ways in which TM
can be manifested: 1) when research participants fail to
recognize that decisions regarding randomization or cer-
tain aspects of the research procedures (e.g., dosages
and duration of administered drugs) will not be indivi-
dualized to their personal needs (TM1); or 2) when
research participants hold an unreasonable appraisal of
the nature or likelihood of medical benefit from their
study participation (TM2) [23]. Essentially, research par-
ticipants might hold mistaken beliefs about how the
research will be executed (TM1) or is designed in a
manner to ensure direct benefits to them (TM2) [22].
Investigators have explored the frequency and the fac-
tors (both participant- and study-related) that might
underlie the existence of TM in clinical research
[23,25-27]. In a study involving patients in different
types of clinical trials, those with greater age, lower
levels of education, poorer health and functional status,
and those with greater optimism about their health in
t h ef u t u r ew e r ea th i g h e rr i s kf o rm a n i f e s t i n gT M[ 2 3 ] .
In another study involving early-phase gene transfer
trials, participants with cancer or vascular diseases
exhibited TM more frequently than those with inherited
or infectious diseases. Also, the presence of TM was sig-
nificantly less in patients who received a consistent mes-
sage that benefits were unlikely compared with those
who did not receive any such messages [26]. Finally, in
a study involving more than 270 patients enrolled in
clinical trials, TM was present in 70% of respondents
and it presence was positively associated with the acute-
ness and severity of the disease [27].
T h ep r e s e n c eo fT Mm i g h tb ee x p l a i n e db yp a r t i c i -
pants’ knowledge gap regarding how clinical research
and patient care differ in their purpose, characteristic
methods, and justification of risks [21]. Alternatively, it
might be due to participants’ misplaced trust in
researchers, thinking that they will act as their physi-
cians who will protect them, as well as promote their
individual health interests [28]. Finally, the conduction
of research studies in the clinical setting might reinforce
the presence of treatment relationships and individua-
lized care. Accordingly, many patients who enroll in
research might think that their care will still be indivi-
dualized to match their personal medical needs even in
the context of a research study [29]. Such perceptions
might be enhanced by the use of certain language found
in consent forms (such as “doctor” instead of “investiga-
tor,” and “treatment” instead of “intervention”), the
“therapeutic” discourse used by nurses and physicians
conducting clinical trials [30], or the recruitment of
patients into clinical trials by investigators who also
their primary physicians.
There are two major ethical concerns with the TM.
First, failure to appreciate correctly the risks and bene-
fits of research participation raises concerns regarding
the validity of informed consent [21,23]. Second, the
presence of TM reflects the very real possibility that
research participants will see the investigator’sr o l ea s
that of the physician and view an invitation to enroll in
research as a professional recommendation that is
intended to serve their individual treatment interests.
Such inappropriate enrollment of patients into research
reflects a concern with exploitation [31].
Methods to enhance informed consent for
participation in clinical trials
The written, informed consent form (ICF) can be instru-
mental in enhancing subject comprehension. A study
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cal trials showed that careful reading of the consent
form was associated with improved knowledge scores
[25]. Other studies have demonstrated greater compre-
hension in those subjects who have carefully read the
consent form [32,33], but these findings were associated
with individuals with higher education levels. This result
is not surprising considering that many IRB-approved
ICFs are written at a reading level that is above that of
the general population [34-36].
To enhance subject understanding, commentators have
recommended the use of shorter, simplified forms con-
taining language at or below the eighth-grade reading
level [37,38]. Studies have demonstrated that certain
modifications in the written ICF could lead to enhanced
subject comprehension. Dresden and Levitt [39] showed
that subjects were able to retain more information from a
modified, shortened version (reading level = 8.7) than
from a standard, industry consent form (reading level =
12.0). Young et al. [40] reported significantly higher sub-
ject comprehension using a simplified form (sixth-grade
level) compared with a standard form (16th grade level).
Another study showed that self-reported understanding
by patients tended to be highest when consent forms
were written at a lower grade level [33]. These results
suggest that shorter ICFs written at a lower reading level,
when read carefully, might enhance subject understand-
ing. Recently, the Acute Respiratory Distress Syndrome
Clinical Trials Network (ARDSNet) investigators pub-
lished an informed consent template exclusively for criti-
cal care research that is written at an eighth-grade
reading level, highlights key research concepts, and uses
language to minimize the therapeutic misconception (e.
g., avoidance of words, such as “treatment,”“ therapy,” or
“medication,” which might imply that the agent or proce-
dure has some proven efficacy; and use of “investigator”
or “study doctor” instead of the word “doctor”) [41].
In addition to the format and structure of the consent
forms, the use of alternative media or methods for pre-
senting information might enhance comprehension. A
recent review analyzed the existing literature on inter-
ventions to improve research participants’ understanding
of information disclosed in the informed consent pro-
cess [42]. The analysis reviewed five categories of inter-
ventions: multimedia presentations, enhanced consent
forms, extended discussions, test/feedback, and “other.”
The results showed that the use of multimedia and
enhanced consent forms had only limited success,
whereas having extended discussions appeared to be the
most effective method of improving understanding.
Methods to assess capacity
Practices regarding the obtainment of informed consent
from critically ill patients differ among researchers. For
example, in the ARDSNet trials involving critically ill
patients receiving mechanical ventilation (Low Tidal
Volume Trial and the Fluids and Catheter Treatment
Trial), approximately 1% of research subjects were
deemed competent to provide their own consent. How-
ever, there was considerable variability between the clin-
ical centers with regards to the proportion of critically
ill patients who gave informed consent themselves
(range between 0% and 16.3%) [11]. This variability
coupled with the lack of a specific plan to assess deci-
sion-making capacity by many of the ARDSNet clinical
centers might question the validity of the informed con-
sent process. The failure to assess capacity can be pro-
blematic, because incorrect judgments that potential
vulnerable subjects are capable of exercising autonomy
might involve them in research involuntarily. Accord-
ingly, commentators have suggested that researchers
assess subjects’ comprehension as part of the informed
consent process [43-45].
Currently, there are no universally accepted proce-
dures regarding capacity assessment for critical ill
patients. However, there are several well-validated mea-
sures for evaluating informed consent capacity for deci-
sion making in the research setting [46]. Many of these
instruments are time-consuming in its application, thus
making it somewhat undesirable for use as a screening
measure in most research studies with critically ill
patients. Alternatively, a shorter measure is the Univer-
sity of California, San Diego (UCSD), Brief Assessment
of Capacity to Consent (UBACC) instrument, which is a
10-item measure that uses questions pertaining to
understanding and appreciation of information [47].
Less formal capacity assessments can consist of using
probing questions to assess the potential subjects’
understanding of the involved research. Johnson-Greene
[44] recommend the following examples of probing
questions that researchers could ask after describing the
research:
1. Can you tell me what will happen if you decide to
be in this study?
2. Will being part of this study help you?
3. Can anything bad happen to you if you are part of
this study?
4. Can you decide not to be part of this study?
Also recommended is that when asking probing ques-
tions to assess capacity, researchers should avoid the use
of leading questions or close-ended questions that elicit
a “Yes” or “No” response. This recommendation reso-
nates with the previous-mentioned finding that compre-
hension is enhanced when investigators have extended
discussions with potential research participants. In other
words, being able to have conversations with potential
participants is crucial in explaining the research protocol
and assessing their capacity. Since having such
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tion is difficult, the feasibility of enrolling such patients
with their own informed consent might be problematic,
especially if these patients are receiving or have received
sedatives. One approach to patients who are receiving
mechanical ventilation is to assess whether such patients
have some decisional capacity and, if present, obtain
their assent in conjunction with the consent of their
proxies (similar to what is done with children).
Issues involved with proxy consent
Although many critically ill patients have, or are at risk
of having, decisional impairment, consensus statements
on research ethics assert that ethically acceptable
research may proceed with such vulnerable subjects
with appropriate proxy consent [2,3]. Both the United
States federal regulations [7] and the European Directive
[8,9] require proxies who give consent for subjects’ par-
ticipation in research to be legally authorized under
applicable law to provide such consent.
Who shall serve as the legal authorized representative
(LAR) for the patient is determined by the laws of the
respective state in the United States or by the national
law of the individual European Union member nation.
LARs might include persons previously appointed
through a legal process (e.g., legal guardian). Alterna-
tively, laws might confer automatic legal authorization
to existing “natural persons” (such as a family member
or a friend). Without laws that give such automatic legal
authorization to family or friends, many previously
healthy persons who become temporarily incapacitated
due to critical illness may not be able to participate in
many types of critical care research, because they had
not previously appointed a legal representative.
Whether state laws were in existence that gave legal
authorization to family members to provide consent was
a recent focus of OHRP in the ARDSNet trials [45]. In
European countries with laws that define a narrow inter-
pretation of “legal representatives,” researchers have
reported extensive difficulties with enrolling patients in
research [9,48].
There are two decision-making standards for proxy
consent. If possible, proxies should appeal to the “substi-
tuted judgment” standard, whereby decisions for incapa-
citated patients are based on a good faith judgment of
what subjects would have chosen if capable of making a
decision themselves. However, such a standard is fre-
quently unrealistic because proxies often do not know
patients’ previous preferences [49,50]. Accordingly,
proxies should consider what would be in the “best
interests” of the patient. Regardless of the decision-mak-
ing standard used to provide consent, proxies should be
appropriately qualified (e.g., properly acquainted with
the patient and available to be present during the course
of the research so that they will be ready to revoke con-
sent if the burdens become too great) and not subject to
potential conflicts of interest [9]. Also, studies have
shown high levels of anxiety and psychological distress
in family members of critically ill patients, which might
impair their ability to give adequate informed consent
for research participation for incapacitated patients
[51,52].
Core safeguards for vulnerable subjects
Although the U.S. regulations are silent regarding speci-
fic safeguards to provide additional protections to adults
unable to provide consent, other guidelines have pro-
posed the following safeguards: 1) assessment of sub-
jects’ decision-making capacity; 2) respect for subjects’
assent and dissent; 3) a process to obtain re-consent if
and when the subjects regain capacity; 4) “necessity”
requirement to ensure that research cannot be per-
formed without enrolling incapacitated adults; 5) “sub-
ject-condition” requirement, whereby the research
involves a condition from which the subject suffers; 6)
an independent participation monitor to monitor sub-
jects’ involvement as they progress through the study
protocol; 7) an independent consent monitor to monitor
the consent process and assess subject’s capacity; and 8)
sufficient evidence of subjects’ prior preferences and
interests [1,5,53,54].
One study surveyed the practices of 104 IRBs from a
random sample of U.S. institutions and demonstrated
much variability regarding the requirement of safeguards
and limits on risks for research involving adults with
impaired decision-making capacity [10]. For example,
the survey results showed the percentage of IRBs that
would “always” or “very frequently” require the following
safeguards: determination of consent capacity for
patients in the intensive care unit (56%); presence of
assent or dissent from patients (50%); presence of an
independent monitor to provide assurance that research
participation is consistent with the patient’s interest
(13%); re-consent of the subjects once decision-making
capacity returns (75%); and evidence of the patient’s pre-
vious preference for research (27%).
Regarding allowable risk-to-benefit ratios, this survey
study showed that for research with potential for direct
benefit, 62% of IRBs had no limits on acceptable risks
and 24% would limit risks to no more than a minor
increment over minimal risk. International guidelines
also differ on the allowable risk levels for studies invol-
ving adults who lack decision-making capacity [55]. For
research with no prospect of direct benefit, 14% of IRBs
would not allow research of any risk to involve incapaci-
tated adults, whereas 39% would allow only minimal risk
research, and 25% would allow research with minimal
risk and those with a minor increase over minimal risk.
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vulnerable subjects, the risk of research procedures that
do not offer a prospect of direct benefit should be capped
at the level of minimal risk [5,56,57]. This position reflects
the concern that vulnerable subjects should not be put at
undue risk for the sake of society and that such research is
exploitative. However, advocating such a risk ceiling
would seriously impair important research. Also, there is
justification for allowing research procedures without a
prospect of direct benefit and no more than a minor incre-
ment above minimal risk. For example, with a concept of
minimal risk reflecting an absolute standard linked to
socially acceptable risks, procedures that involve a minor
increment above minimal risk would pose no significant
threat to the subject’s health. Procedures common in criti-
cal care research relevant to this risk category would
include non-contrast CT scans and the obtainment of
additional bronchoalveolar lung (BAL) fluid in patients
undergoing this procedure for clinical diagnostic purposes.
Commentators have recommended a framework deli-
neating safeguards linked to permissible risk levels of
the proposed protocol procedures [45]. Table 1 shows a
proposed hierarchy of risk levels and associated safe-
guards. The risk levels and benefit factors presented
refer to the individual procedures of the study, rather
than the research study as a whole. Indeed, a research
study may consist of several procedures or distinct com-
ponents: those with and those without a prospect of
direct benefits. The latter would include those done
solely to gather data to answer a research question. In
the absence of such a component analysis, procedures
performed solely for research purposes might claim to
be justified by the procedures that offer the prospect of
direct benefits to subjects [58]. Because any given proto-
col may contain many procedures and hence, a range of
risk levels, the selection of the essential safeguards to
protect vulnerable subjects should be based on highest
risk level present in the protocol.
For research involving vulnerable subjects at all risk
levels, the following safeguards are recommended:
1) Investigators outline a specific plan to assess the
capacity of all potential subjects when groups that might
involve persons with decisional impairment are targeted
for research, for example, critically ill patients;
2) Proxy consent for those subjects found to lack deci-
sion making capacity;
3) For subjects found to lack decision making capacity
to consent, there should be a requirement for assent,
which entails that investigators obtain affirmative agree-
ment to research participation from subjects whose
capacity is considerably but not completely diminished.
Such subjects might still be able to understand some
aspects of a study. In a similar construct, expressions of
dissent should be respected; and
4) A process for re-consent, which entails that subjects
who were previously impaired and who regain capacity
should be asked for their personal consent, regardless of
whether the procedures in the research are completed.
For research with procedures involving more than
minimal risk and offer the prospect of direct benefits, an
additional safeguard would be to ensure the availability
of an independent person to monitor the subject’s invol-
vement in the study, mainly to determine when it might
be appropriate to withdraw the subject from the study.
The subject’s legally authorized representative could
ordinarily fulfill this role of a participation monitor.
For research with procedures involving no more than
a minor increment above minimal risk and do not offer
the prospect of direct benefits, additional safeguards for
this risk level include:
Table 1 Risk levels and essential safeguards for research studies involving critically ill patients
Risk level Proposed safeguards
Level I: Procedures do not involve greater than minimal
risk for any research.
￿ A written plan describing methods to assess decision making capacity
If subjects do not have capacity to provide consent, then:
￿ Proxy consent;
￿ A process to respect assent and dissent of the subjects;
￿ A process to obtain re-consent from the subjects if and when subjects regain capacity
Level II: Procedures of the research involve greater than
minimal risk and offer the prospect of direct benefits.
￿ Level I safeguards
￿ Participation monitor: availability of an independent person to monitor the subject’s
involvement in the study, e.g., the subject’s legal authorized representative.
Level III: Procedures of the research do not involve greater
than a minor increment above minimal risk and do not
offer the prospect of direct benefits.
￿ Level I and II safeguards
￿ Necessity requirement
￿ Subject condition requirement
Level IV: Procedures of the research involve greater than
minimal risk and do not offer the prospect of direct
benefits.
￿ Level I, II, and III safeguards
￿ Independent consent monitor
￿ Evidence of the subject’s preferences and interests.
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jects with decisional impair m e n ts h o u l db ee n r o l l e di n
research only when their participation is scientifically
necessary, for example, when the desired information
cannot be obtained by enrolling adults who can consent;
and
2) Subject condition requirement, whereby the
research must involve a condition from which the sub-
ject suffers.
The most controversial category of research are stu-
dies containing procedures with no prospect of direct
benefits and present more than a minor increment
above minimal risk. Due to the potential for serious
harm and exploitation, an independent consent monitor
should be available who could assess decision-making
capacity and assess evidence of the subject’sp r i o rp r e -
ferences and interests to participate in research.
Conclusions
The ethical conduct of research is complex, evolving,
and harbor potential harms and infringement of rights
to subjects who participate in such research. This is
especially true for research involving critically ill
patients, many of whom are vulnerable due to potential
decisional incapacity and the setting of the research
itself. Heightened awareness to principles of ethics and
incorporation of procedures to enhance the informed
consent process and the provision of additional safe-
guards to enhance protections of vulnerable subjects
would help maintain the public trust in the research
endeavor.
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